RSV protection for aboriginal infants
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This study tests an RSV antibody shot that helps protect babies from severe RSV. It aims to see how well this preventive shot works in Aboriginal and Torres Strait Islander infants when given around 6-9 months of age.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby must be an Aboriginal and/or Torres Strait Islander infant aged between 6 and 9 months.
- You must be willing to give informed consent and take part in all study procedures, including review of medical records.
- Your baby must not have already received the RSV vaccine (nirsevimab) at 3 months of age or older.
- Your baby must not be currently sick with a fever or respiratory infection at the time of screening (can join later once recovered).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new injection (SIBP-A16) designed to protect infants against RSV, a common virus that can cause serious lung infections in babies. The trial will see if the injection is safe and works in both premature and full-term infants during their first RSV season.
This study tests a new vaccine that may protect babies from a common breathing virus called RSV. It is given to healthy women to see if it is safe and if it helps the body make protection that could be passed to a baby during pregnancy.
This study looks at babies in Brazil who develop breathing or cold-like symptoms, to see how well the RSV vaccine given to mothers during pregnancy protects infants from severe RSV illness. If your baby is under 1 year old and has respiratory symptoms, they may be able to join.
This trial studies whether giving a booster dose of the RSV vaccine (Abrysvo) is safe and effective for adults with weakened immune systems. It includes people who have never had an RSV vaccine and those who had one or two doses in the past.
This trial tests an experimental vaccine against respiratory syncytial virus (RSV) in children who are at high risk of serious RSV illness due to chronic medical conditions or weakened immune systems. The goal is to see if the vaccine is safe and effective in preventing RSV-related lower respiratory tract infections.
This study tests a new vaccine designed to protect against respiratory syncytial virus (RSV), a common virus that can cause serious lung infections. The vaccine is given as a shot, and the study will check how your immune system responds to it.
Hear when a new Respiratory Syncytial Virus (RSV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.